VetMedOsteosarcoma bone pain in dogs: IV bisphosphonate (pamidronate/zoledronate) vs placebo — MAYBE (weak evidence) (the treatment made no difference)
In dogs with appendicular osteosarcoma managed without amputation, does IV bisphosphonate (zoledronate/pamidronate) reduce bone pain vs placebo?
Shelf #112 · gate-verified and displayed under the developer's blinded-trial rule
MAYBE (weak evidence) (the treatment made no difference): The only placebo-controlled test on this shelf was null on its primary pain outcome. In Fan 2009, a randomised, prospective, double-blinded, placebo-controlled trial of 50 dogs with appendicular osteosarcoma receiving standardised palliative therapy (radiotherapy plus IV doxorubicin), adding pamidronate did not improve pain relief: median duration of subjective pain relief was 76 days with pamidronate vs 75 days on placebo (P = .39), and durable analgesia (≥112 days) occurred in 11/26 pamidronate dogs vs 9/24 placebo dogs. The draft anchor for this shelf described a Fan programme of placebo-controlled studies (plural) of bisphosphonates — that is not what the records show: there is ONE placebo-controlled pamidronate trial, it tested pamidronate added to radiotherapy and doxorubicin (not bisphosphonate alone), and there is NO placebo-controlled zoledronate trial in this population (a PubMed search for a randomised placebo zoledronate study returned no records). The zoledronate evidence is a prospective uncontrolled study (Fan 2008) in which owner-reported improved limb usage coincided with bone-marker changes in a subset also receiving oral analgesics, and the single-agent pamidronate evidence (Fan 2007) is likewise uncontrolled: 12 of 43 dogs (28%) had pain alleviation for >4 months, a pattern equally consistent with the concurrent NSAID therapy, natural variation, or a real subset effect. Bisphosphonates do measurably suppress bone resorption in these dogs (Fan 2005, Fan 2008), and in Fan 2009 the dogs that achieved durable pain control on pamidronate showed greater falls in urine N-telopeptide and larger rises in tumour bone density than placebo dogs in the same subgroup — a biologic signal in a post-hoc subgroup, not a pain benefit for treated dogs overall. Drafted Nov 10, 2026 (VetMed build, topic #112); all figures from abstracts fetched and verified at drafting.
Fan 2009: adding pamidronate to palliative radiotherapy and doxorubicin did NOT improve pain relief — median 76 vs 75 days on placebo (P = .39)
Randomized, prospective, double-blinded, placebo-controlled study (record's own wording); publication type Randomized Controlled Trial
Who: Dogs: 50 dogs with appendicular osteosarcoma in a clinical palliative-care setting, treated with standardized palliative therapy (palliative radiotherapy and intravenous doxorubicin) and either adjuvant pamidronate (n = 26) or sterile saline placebo (n = 24); responses serially evaluated by subjective pain scores, urine N-telopeptide excretion, primary tumour relative bone mineral density, and computerized pressure-platform gait analysis.
Result: Median duration of subjective pain relief was 76 days for dogs treated with adjuvant pamidronate and 75 days for placebo (P = .39). Forty percent (20/50) of dogs experienced durable analgesia, defined as pain alleviation ≥112 days — pamidronate 11/26 and placebo 9/24. For patients achieving durable pain control, dogs treated with pamidronate achieved greater reductions in N-telopeptide excretion and larger increases in relative bone mineral density compared with placebo controls. Changes in peak vertical force on gait analysis correlated with pain alleviation. The authors conclude combining pamidronate with standardized palliative therapy is safe, but does not clearly improve pain alleviation.
Watch out: This is the claim-carrying card and its primary result is null — the stamp carries that on its face. Note what was actually tested: pamidronate ADDED to radiotherapy plus doxorubicin, not a bisphosphonate alone against placebo, so the trial cannot exclude an effect of pamidronate in a dog receiving no other palliative therapy. The N-telopeptide/bone-density signal comes from the subgroup that achieved durable pain control, a post-hoc subgroup comparison, not a randomised comparison of all treated dogs.
Fan TM, Charney SC, de Lorimier LP, Garrett LD, Griffon DJ, Gordon-Evans WJ, Wypij JM. Double-blind placebo-controlled trial of adjuvant pamidronate with palliative radiotherapy and intravenous doxorubicin for canine appendicular osteosarcoma bone pain. J Vet Intern Med. 2009;23(1):152-60. PMID: 19175734. Registry ID: none in the record. MeSH: Analgesia/veterinary · Analgesics/administration & dosage,therapeutic use · Animals · Antineoplastic Agents/administration & dosage,therapeutic use · Bone Density Conservation Agents/administration & dosage,therapeutic use · Diphosphonates/administration & dosage,therapeutic use · Dog Diseases/drug therapy,radiotherapy · Dogs · Double-Blind Method · Doxorubicin/administration & dosage,therapeutic use · Extremities/pathology · Female · Male · Osteosarcoma/complications,veterinary · Pain Management · Pamidronate · Radiotherapy/veterinary
Fan 2007: single-agent pamidronate (with NSAIDs) — 12 of 43 dogs (28%) had pain alleviation for >4 months, median 231 days in that subset
Prospective study (record's own wording; no control group, randomisation and blinding not stated)
Who: Dogs: 43 dogs with naturally occurring appendicular osteosarcoma in a clinical setting, administered pamidronate intravenously with nonsteroidal anti-inflammatory drugs (NSAID); responses evaluated by a numerical cumulative pain index score (CPIS), urine N-telopeptide excretion, and relative primary tumour bone mineral density by dual-energy x-ray absorptiometry.
Result: Twelve of 43 dogs (28%) had pain alleviation for >4 months, lasting a median of 231 days. Changes in CPIS and relative bone mineral density during treatment were statistically different between responders and nonresponders (P = .046 and .03, respectively). The authors conclude that, substantiated by reductions in CPIS and increases in bone mineral density, single-agent pamidronate administered intravenously with NSAID therapy relieves pain and diminishes pathologic bone turnover in a subset of dogs.
Watch out: No control group of any kind: every dog got pamidronate and an NSAID, so the 28% responder figure cannot be separated from NSAID effect, owner/expectation effects on a subjective pain index, or the natural course. Read against Fan 2009 above — where 9/24 placebo dogs (on radiotherapy and doxorubicin) also achieved durable analgesia — an uncontrolled responder subset is not evidence the drug caused the relief.
Fan TM, de Lorimier LP, O'Dell-Anderson K, Lacoste HI, Charney SC. Single-agent pamidronate for palliative therapy of canine appendicular osteosarcoma bone pain. J Vet Intern Med. 2007;21(3):431-9. PMID: 17552447. Registry ID: none in the record. MeSH: Animals · Antineoplastic Agents/therapeutic use · Biomarkers, Tumor/urine · Bone Density/drug effects · Bone Neoplasms/complications,drug therapy,veterinary · Collagen Type I/urine · Diphosphonates/therapeutic use · Dog Diseases/drug therapy,etiology · Dogs · Female · Injections, Intravenous/veterinary · Male · Osteosarcoma/complications,drug therapy,veterinary · Pain/drug therapy,epidemiology,etiology,veterinary · Palliative Care · Pamidronate · Peptides/urine · Prospective Studies · Treatment Outcome
Fan 2008: zoledronate suppressed bone-resorption markers in dogs with malignant osteolysis; owner-reported better limb use in an osteosarcoma subset also on oral analgesics
Prospective study (record's own wording; no control group, randomisation and blinding not stated)
Who: Dogs: 6 healthy dogs and 20 dogs with naturally occurring primary or metastatic bone tumours (including 10 dogs with osteosarcoma) in a clinical/experimental setting, administered zoledronate intravenously; bone biologic effects evaluated by serum C-telopeptide and urine N-telopeptide concentrations and, in the osteosarcoma dogs, serial primary tumour relative bone mineral density; biochemical tolerability assessed in 9 dogs receiving ≥2 consecutive treatments.
Result: All dogs had significant reductions in serum C-telopeptide or urine N-telopeptide concentrations or both after zoledronate administration. In a subset of dogs with appendicular osteosarcoma, reduced urine N-telopeptide concentrations and increased primary tumour relative bone mineral density coincided with improved limb usage as reported by pet owners in dogs treated with zoledronate and concurrent oral analgesics. Multiple zoledronate infusions were not associated with biochemical evidence of toxicosis. The authors conclude IV zoledronate exerts bone biologic effects, appears safe, and can provide pain relief.
Watch out: This is the only zoledronate card the records support, and it is not a pain trial: there is no placebo or control arm, no pain score, and the limb-use observation is owner-reported in a subset also receiving oral analgesics. It establishes antiresorptive biologic activity and short-term biochemical tolerability — not that zoledronate reduces bone pain against placebo, which remains untested in a controlled design.
Fan TM, de Lorimier LP, Garrett LD, Lacoste HI. The bone biologic effects of zoledronate in healthy dogs and dogs with malignant osteolysis. J Vet Intern Med. 2008;22(2):380-7. PMID: 18346146. Registry ID: none in the record. MeSH: Animals · Bone Density/drug effects · Bone Density Conservation Agents/pharmacology,therapeutic use · Bone and Bones/drug effects · Cohort Studies · Diphosphonates/pharmacology,therapeutic use · Dog Diseases/drug therapy,etiology · Dogs · Female · Imidazoles/pharmacology,therapeutic use · Male · Neoplasms/complications,veterinary · Osteolysis/drug therapy,etiology,veterinary · Prospective Studies · Zoledronic Acid
Fan 2005: IV pamidronate was clinically safe in 33 cancer-bearing dogs; in 10 osteosarcoma dogs, subjective pain improved in 4 of 10
Prospective safety/biologic-activity study (record's own publication types; no control group)
Who: Dogs: 33 tumour-bearing dogs with primary or secondary bone involvement in a clinical setting, treated with pamidronate at a mean dosage of 1.0 mg/kg IV every 28 days, with biochemical tests of renal function before each successive treatment; biologic activity assessed prospectively in 10 dogs with appendicular osteosarcoma by urine N-telopeptide excretion and primary tumour bone mineral density.
Result: Of 33 dogs treated, 1 dog had clinically relevant increases in serum creatinine and blood urea nitrogen concentrations. In the 10 osteosarcoma dogs, pamidronate reduced urine N-telopeptide excretion (P = .042) and enhanced bone mineral density of the primary tumour (P = .024), and subjective improvement in pain control was reported in 4 of the 10 dogs. The authors conclude IV pamidronate appears clinically safe in tumour-bearing dogs and may possess modest biologic activity for managing neoplastic complications of pathologic bone resorption.
Watch out: The pain observation is 4 of 10 dogs, subjective and uncontrolled — context for tolerability and biologic activity, not an efficacy estimate. The renal finding (1 of 33 with clinically relevant creatinine/BUN increases) is the card's most usable figure for practice.
Fan TM, de Lorimier LP, Charney SC, Hintermeister JG. Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary or secondary bone involvement. J Vet Intern Med. 2005;19(1):74-80. PMID: 15715051. Registry ID: none in the record. MeSH: Absorptiometry, Photon/veterinary · Animals · Antineoplastic Agents/administration & dosage · Bone Density/drug effects · Bone Neoplasms/drug therapy,pathology,veterinary · Bone Resorption/drug therapy,veterinary · Collagen/urine · Collagen Type I · Diphosphonates/administration & dosage · Dog Diseases/drug therapy,pathology · Dogs · Female · Infusions, Intravenous · Kidney/drug effects,physiopathology · Kidney Function Tests/veterinary · Male · Osteosarcoma/drug therapy,secondary,veterinary · Pamidronate · Peptides/urine
Synthesis: bisphosphonates suppress bone resorption in these dogs, but the one placebo-controlled pain trial found no added pain relief
Synthesis
Who: Synthesis of the cards above: Fan 2009 (50 dogs, randomised double-blind placebo-controlled, pamidronate added to radiotherapy + doxorubicin), Fan 2007 (43 dogs, prospective uncontrolled single-agent pamidronate + NSAID), Fan 2008 (6 healthy dogs + 20 dogs with malignant osteolysis including 10 with osteosarcoma, prospective uncontrolled zoledronate) and Fan 2005 (33 cancer-bearing dogs, prospective pamidronate safety/biologic activity, 10 with osteosarcoma).
Result: The consistent findings are: (1) pain — the only controlled comparison is null: median subjective pain relief 76 vs 75 days, P = .39, with durable analgesia in 11/26 vs 9/24 dogs (Fan 2009); uncontrolled series report responder subsets (12/43 on pamidronate + NSAID; 4/10 subjective improvement in the earliest series) that the placebo arm's own responder rate makes uninterpretable as drug effect; (2) biology — both pamidronate and zoledronate reduce bone-resorption markers (urine N-telopeptide, serum C-telopeptide) and can raise primary tumour bone mineral density, and in Fan 2009 those biologic changes were larger in pamidronate dogs that achieved durable pain control; (3) safety — IV pamidronate at ~1.0 mg/kg every 28 days produced one clinically relevant renal-function increase in 33 dogs, and repeated zoledronate infusions showed no biochemical toxicosis in 9 dogs. No controlled trial of zoledronate for pain exists in these records.
Watch out: The question as drafted named zoledronate and pamidronate together against placebo; the records split them — pamidronate has the (null) placebo trial, zoledronate has only uncontrolled biologic data, and neither was tested as a bisphosphonate alone against placebo in dogs receiving no other palliative therapy. Extrapolating the pamidronate null to zoledronate, or the zoledronate marker data to a pain claim, would both go beyond the records.
Synthesis of Fan TM et al. PMID: 19175734; Fan TM et al. PMID: 17552447; Fan TM et al. PMID: 18346146; Fan TM et al. PMID: 15715051. Registry IDs as on the individual cards.
Back to the library index · VetMed home
VetMed is an educational resource, not veterinary advice.